Gut microbiota‐derived trimethylamine‐N‐oxide inhibits SIRT1 to regulate SM22α‐mediated smooth muscle cell inflammation and promote atherosclerosis progression
Journal of Cell Communication and Signaling · 2025-06 · 19 (2)
DOI: 10.1002/ccs3.70021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Communication and Signaling, online erschienen am 06.06.2025. Verfasst von Yajuan Yin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology The First Hospital of Hebei Medical University Shijiazhuang Hebei China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebei Provincial Postdoctoral Science Foundation, Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
Atherosclerosis (AS) is a prevalent cardiovascular disease, and emerging evidence highlights the critical role of gut microbiota in its development. Trimethylamine‐N‐oxide (TMAO), a metabolite derived from gut microbiota, is thought to promote AS progression by regulating smooth muscle protein 22‐alpha (SM22α)‐mediated inflammation in vascular smooth muscle cells. This study aims to explore the molecular mechanisms of TMAO in AS through multi‐omics analysis, particularly its effects on SIRT1 inhibition and SM22α modulation. 16S ribosomal RNA sequencing revealed an altered gut microbiota composition in AS mice, characterized by increased Bacteroides and decreased Firmicutes. Metabolomics analysis indicated elevated levels of TMAO in AS mice. Transcriptomic data and cell experiments further confirmed that TMAO promotes AS by regulating SM22α‐mediated inflammation via SIRT1 regulation. These findings suggest that TMAO accelerates progression through the SIRT1 and SM22α‐related pathways, offering novel therapeutic targets for AS intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology The First Hospital of Hebei Medical University Shijiazhuang Hebei China.
- Department of Medical Affaires The First Hospital of Hebei Medical University Shijiazhuang Hebei China.
- Hebei Key Laboratory of Cardiac Injury Repair Mechanism Study Shijiazhuang Hebei China.
- Hebei Key Laboratory of Heart and Metabolism Shijiazhuang Hebei China.
- Hebei Engineering Research Center of Intelligent Medical Clinical Application Shijiazhuang Hebei China.
- Hebei International Joint Research Center for Structural Heart Disease Shijiazhuang Hebei China.
ORCID-Profile: Fangfang Ma
Förderung
- Hebei Provincial Postdoctoral Science Foundation
- Natural Science Foundation of Hebei Province
Zitieren
APA
Yin, Y., Wei, M., Jiang, X., Liu, M., Shi, X., Zhang, X., Wang, L., Liu, G., Zheng, M., & Ma, F. (2025). Gut microbiota‐derived trimethylamine‐N‐oxide inhibits SIRT1 to regulate SM22α‐mediated smooth muscle cell inflammation and promote atherosclerosis progression. Journal of Cell Communication and Signaling, 19(2). https://doi.org/10.1002/ccs3.70021
Vancouver
Yin Y, Wei M, Jiang X, Liu M, Shi X, Zhang X, et al. Gut microbiota‐derived trimethylamine‐N‐oxide inhibits SIRT1 to regulate SM22α‐mediated smooth muscle cell inflammation and promote atherosclerosis progression. Journal of Cell Communication and Signaling. 2025;19(2). doi:10.1002/ccs3.70021
BibTeX
@article{Yin2025,
author = {Yin, Yajuan and Wei, Mei and Jiang, Xiufang and Liu, Mei and Shi, Xiaocui and Zhang, Xiao and Wang, Le and Liu, Gang and Zheng, Mingqi and Ma, Fangfang},
title = {Gut microbiota‐derived trimethylamine‐N‐oxide inhibits SIRT1 to regulate SM22α‐mediated smooth muscle cell inflammation and promote atherosclerosis progression},
journal = {Journal of Cell Communication and Signaling},
year = {2025},
volume = {19},
number = {2},
doi = {10.1002/ccs3.70021}
}
EUVIMED